Photo from wikipedia
The phase 3 POLO study demonstrated a significant progression‐free survival (PFS) benefit and preserved health‐related quality of life (HRQOL) for active maintenance treatment with olaparib vs placebo in patients with… Click to show full abstract
The phase 3 POLO study demonstrated a significant progression‐free survival (PFS) benefit and preserved health‐related quality of life (HRQOL) for active maintenance treatment with olaparib vs placebo in patients with metastatic pancreatic cancer and a germline BRCA mutation. Here, we present a post hoc analysis of the patient‐centered outcomes: time without significant symptoms of disease progression or toxicity (TWiST) and quality‐adjusted TWiST (Q‐TWiST).
Keywords:
metastatic pancreatic;
germline brca;
pancreatic cancer;
active maintenance;
cancer;
polo study
Journal Title: Cancer
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!